Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease

  title={Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease},
  author={W. Schuyler Jones and Iris Baumgartner and William R. Hiatt and Gretchen M. Heizer and Michael S. Conte and Christopher J. White and Jeffrey S. Berger and Peter H. Held and Brian G. Katona and Kenneth W. Mahaffey and Lars Norgren and Juuso Blomster and Marcus Milleg{\aa}rd and Craig J. Reist and Manesh R. Patel and F. Gerry R. Fowkes},
  journal={Journal of Vascular Surgery},

Figures and Tables from this paper

Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial

Patients with PAD and prior CAD had higher composite rates of cardiovascular death, MI, and ischemic stroke versus PAD without diagnosed CAD, and there were no significant differences between ticagrelor and clopidogrel in cardiovascular events or major bleeding.

Rivaroxaban in Peripheral Artery Disease after Revascularization.

In patients with peripheral artery disease who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone.

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization

Rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for acute limb ischemia regardless of clopidogrel use, and these data support the addition of rivar oxaban to aspirin after lower extremity revascularization regardless of concomitant clopinogrel.

A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative.

This structured review is to assess the available randomized data for antithrombotic therapy after peripheral arterial revascularization, with a focus on clinical trial design issues that may affect interpretation of study results, and highlight areas that require further investigation.

Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.

This is a subanalysis of a previously reported subgroup of patients with symptomatic LE-PAD who were enrolled in a large, double-blind, placebo-controlled randomized clinical trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies [COMPASS]) in 602 centers in 33 countries and found patients with high-risk limb presentations or high- risk comorbidities had a high incidence of major vascular events.

Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID.

Prior peripheral revascularization, baseline atrial fibrillation, and lower ABI identify PAD patients at heightened risk for ALI, an event associated with subsequent cardiovascular and limb-related morbidity and mortality.

Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD.

Low-dose rivaroxaban plus aspirin reduces ALI after LER, including ALI events associated with the most severe outcomes, and is consistent regardless of revascularization approach or clopidogrel use.

Antithrombotic treatment in peripheral artery disease.

Rivaroxaban plus aspirin is the first antithrombotic association that proved significant benefit for PAD patients, in terms of strong endpoints - total mortality and cardiovascular mortality.

Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial.

Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials

The EUCLID trial's evidence of neutrality between clopidogrel and ticagrelor sheds light into the complexity of studying the PAD population and the continued need to meticulously design trials to investigate the optimal therapies.



Long-term use of ticagrelor in patients with prior myocardial infarction.

In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, my Cardiac Infarction, or stroke and increased therisk of major bleeding.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.

A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.

Medical Therapy in Peripheral Artery Disease

Despite the level and degree of limb symptoms, even asymptomatic persons with PAD have a greatly reduced functional capacity, which suggests that occlusive disease in the lower extremity is associated with reduced exercise capacity and functional status regardless of the symptomatic state.

Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.

There is a wide range of leg symptoms in persons with PAD beyond that of classic IC, and functional impairments are found in every PAD symptom group, and the degree of functional limitation varies depending on the type of leg symptom.